Document is current

Article History

Received: 21 March 2025

Accepted: 23 June 2025

First Online: 3 September 2025

Competing interests

: N.R. reports grants from AbbVie, Eiger Biopharmaceuticals, Gilead Sciences, Inc., and Salix Pharmaceuticals; consulting fees from Gilead Sciences, Inc., and Salix Pharmaceuticals; and is an advisory board member for Arbutus Biopharma. J.V.L. reports grants and speaker fees from AbbVie, Echosens, Gilead Sciences, Inc., Janssen, Merck Sharp & Dohme, Novo Nordisk, Roche Diagnostics, and ViiV Healthcare, and consulting fees from Echosens, the Global NASH Council, GSK, Novavax, Novo Nordisk, and ProSciento. S.S. reports grants, products, and speaker fees from Gilead Sciences, Inc., and grants and products from Abbott Laboratories. A.M. reports support for attending meetings and/or travel from Gilead Sciences, Inc., and Ipsen; speaker fees from Angelini Pharma, Gilead Sciences, Inc., and Roche; and consulting fees from Akero Therapeutics, Gilead Sciences, Inc., and Madrigal Pharmaceuticals. M.L.Y. reports grants from AbbVie, Bristol Myers Squibb, Gilead Sciences, Inc., Merck, and Roche Diagnostics, and reports consulting and speaker fees for AbbVie, Bristol Myers Squibb, Gilead Sciences, Inc., and Roche. H.R. is a member of advisory boards for AbbVie, Abbott, Gilead Sciences, Inc., Janssen, Merck, Roche, and VBI Vaccines. All proceeds from advisory board participation were donated to the Center for Disease Analysis Foundation. The Center for Disease Analysis Foundation has received research funding from Assembly Biosciences, AbbVie, Boehringer Ingelheim, Gilead Sciences, Inc., Intercept Pharmaceuticals, Merck, Novartis, Pfizer, and Roche.